Key Takeaways
- Best growth in two years, margin reset: Revenue jumped 12.7% QoQ (28.2% YoY) as acquisitions and volumes kicked in, while EBITDA margin compressed 220 bps to 21.7% on pay hikes, GenAI investment, and a new sales engine.
- Acquisitions are integrated and cross-selling: PureSoftware and Aureus are now fully consolidated; joint go-to-market is active, including taking GenAI services to PureSoftware's large global financial services client.
- GenAI is moving from POC to production, selectively: IT organizations are converting high-priority use cases while deferring lower-priority ones; the company is building repeatable semi-finished solutions to improve margin on follow-on sales.
- The path to 30% growth is back-end loaded: Management needs over 6% sequential growth in each of the next two quarters, leaning on two expected large Arttha banking deals, ramp-up of two new $5M-run-rate customers, and a Q4 budget-release bump.
- What to watch next quarter: Whether the two large Arttha deals close, the pace of GenAI POC-to-production conversion, and whether Q3 furloughs and leadership pay hikes push margins below the guided 20%-22% band.
Growth Engine: What Drove the Quarter
- Serial QoQ acceleration: 12.7% sequential growth built on stable pricing, higher volumes, and the first full quarter of PureSoftware and Aureus contribution, making this the strongest quarter in two years.
- Customer mining deepened: $3M-$5M customers rose from 2 to 6; average revenue per customer reached $842,000; 59 customers now contribute over $1M, and the company worked with 82 billion-dollar corporations.
- All geos and verticals performed: Growth was well-rounded with no single geography or vertical dragging; deep client relationships expanded through account mining.
- H1 crossed ₹1,000 crores: Half-year revenue milestone reached; absolute EBITDA expanded despite investment headwinds.
- On-site mix dropped sharply: The ratio fell from 15.5 to 11.4 as acquired entities brought large offshore benches; management wants to rebuild on-site presence to drive consulting-led front-end business.
Venkatraman Narayanan: "It is pertinent to note that on pay increases, we have gone ahead with our regular cycles, backdrop of many of our peer companies who have either deferred or cancelled their regular cycles."
Margin Walk: The Investment Story
- Pay hikes took 230 bps: Annual increments implemented July 1 were the single largest drag, at a time when peers deferred or cancelled cycles.
- GenAI business consumed 150 bps: ₹9-10 crores invested in the GenAI unit, which is still running at only 20%-25% utilization, creating a deliberate margin overhang.
- New sales engine added cost: The newly created industry groups and Chief Growth Officer-led new logo team are in investment phase, with pipeline building but revenue yet to follow.
- Operating margin fell to 17.9%: Down from 19.8% QoQ, absorbing pay, GBS investment, and sales build-out.
- Utilization slipped to 76.3%: Campus hires and the low-utilization GenAI business pulled the rate down from 78.2%.
- Amortization charge revised downward: A reassessment of PureSoftware and Aureus purchase price allocation reduced the quarterly intangible amortization to ₹14 crores from the previously projected ₹19.1 crores; Pimcore write-off ends soon, trimming this by another couple of crores from next year.
- Q3 margin pressure flagged: Fewer working days, client furloughs, and leadership pay increases will weigh on Q3; management expects to address this within the quarter.
Venkatraman Narayanan: "Margin prediction is the most difficult part."
GenAI: POC to Production, and the Repeatability Bet
- Selective conversion underway: IT organizations are moving high-priority GenAI use cases from POC to production, while lower-priority ones stay deferred by a quarter or two; digital product companies are converting faster because they embed features into SaaS offerings customers will pay for.
- Four repeatable solutions identified: The company is building semi-finished GenAI offerings in research, customer service, learning, and contract management; the first customer is already secured in each area.
- Margin logic on repeat sales: Incremental cost on the second and subsequent deployments is lower while pricing holds, so margins improve with each repeat; eight such orders together become a healthy, high-efficiency book.
- Internal adoption as proof point: SmilesBot (HR policy chatbot) rolled out; talent acquisition teams piloting an in-house GenAI resume matcher.
- GenAI-powered cybersecurity launch: Happiest Minds Secure 360 delivers 3x speed of traditional remediation, and the company won its single largest cybersecurity deal this quarter for a pharmaceutical contract manufacturer.
- Microsoft AI Partner Council: Membership recognizes AI expertise and commitment to the Microsoft AI ecosystem.
Ashok Soota: "The margins will keep improving on those sales because now your own incremental cost, you still charge the customer the same amount. These won't be giant-type orders. But if you then take 8 such orders, then it becomes a very healthy order, and executable with a really high level of efficiency as we go ahead."
Deals & Pipeline: What Must Fire for 30%
- Arttha banking platform is the swing factor: Two large deals expected to close in the next two quarters; the platform is being taken to Philippines and India (previously unexplored for Arttha domestically); revenue from these deals is lumpy and term-license in structure.
- Two $5M-run-rate customers added in H1: Both are expected to ramp up and contribute meaningfully in the second half.
- Bioinformatics deal starts in Q4: A consulting-led engagement with a European health research institute to build an AI/ML data platform; revenue generation begins in Q4.
- Cybersecurity momentum: Won the single largest multimillion-dollar cybersecurity deal (pharmaceutical contract manufacturer) and chosen as strategic cybersecurity partner for one of India's largest banks.
- New logo engine building: Chief Growth Officer Maninder joined in Q2, built a healthy pipeline; accounts will transition to industry managers post-close.
- Q4 is the seasonal peak: Budget releases drive the strongest quarter; the 6-9 month sales cycle means deals initiated now land in Q4.
Vertical & Capability Highlights
- Bioinformatics as a moat: The company has built in-house expertise combining molecular biology, data science, and healthcare domain knowledge; management claims no other Indian firm can deliver this.
- EdTech is mixed: K-12 performed well but is a statistical business tied to upgrade cycles; higher education faces structural headwinds from declining U.S. enrolments and university cost pressure; professional education is evolving faster with more opportunities.
- Industry group restructuring complete: New vertical-aligned organization with dedicated sales teams brings focused specialization and accountability; the new logo team is chartered to pursue larger deals and larger customers.
- Acquisition cross-sell is live: Joint go-to-sales with PureSoftware and Aureus teams; GenAI services already taken to a large global financial services provider from PureSoftware's client base.
- IoT and AI/ML platform wins: Consulting-led IoT platform for a North American energy tech company; AI/ML data platform for a European health research institute.
Ashok Soota: "These are all very high end, very specialized areas, which I believe there is probably nobody within the country would ever be able to deliver because of the expertise we have built up."
People & Capacity
- Attrition ticked up to 14.4%: Trailing twelve-month rate rose from 13.5%, a watchpoint as the company invests in a new sales engine and GenAI talent.
- Utilization dipped on campus hires: The 76.3% rate reflects fresh intake and the GenAI unit's 20%-25% utilization; both are investments in future capacity.
- Delivery centre expansion: Building capacity across Bangalore, Pune, and Noida; looking to expand into a larger Hyderabad centre.
- On-site ratio deliberately low: Management wants to increase on-site presence to win more consulting-led business that drives offshore revenue.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revenue growth | 30% to 35% for the full fiscal year | FY25 |
| EBITDA margin | 20% to 22% guided range | FY25 |
| Sequential growth | Over 6% QoQ in each of the next two quarters (lower end of 30% target) | Q3 and Q4 FY25 |
| Arttha large deals | Close at least 2 large deals | Next 2 quarters |
| Q3 margin impact | Lower working days and leadership pay increases will weigh; to be addressed within Q3 | Q3 FY25 |
| Q4 revenue | Bulk of benefit from large deals including bioinformatics deal to generate revenue | Q4 FY25 |
| Amortization reduction | ₹14.06 crores quarterly charge to reduce by a couple of crores as Pimcore slides off | Beginning of next year |
| Medium-term margin range | Continue at 20% to 22% | Medium term |
| Long-term revenue | $1 billion top line | Post FY30 |
| Growth rate | 20%+ | Next 3-4 years |
Key Metrics
| Metric | Q2 FY25 |
|---|---|
| Revenue | $62.4 million, constant currency growth of 12.7% QoQ and 28.2% YoY |
| Total income | ₹549 crores, growth of 12.1% QoQ and 27.9% YoY |
| EBITDA | ₹119 crores, growth of 1.8% QoQ and 13.4% YoY |
| EBITDA margin | 21.7%, down from 23.9% in Q1; pay increases impacted by ~230 bps, GenAI investments by ~150 bps |
| Operating profit | ₹93 crores, up from ₹92 crores in Q1 |
| Operating margin | 17.9% of revenues, down from 19.8% in Q1 |
| PBT | ₹67 crores |
| Cash EPS | ₹6.18 per share, growth of 9.5% YoY |
| Diluted EPS | ₹3.29 per share, compared to ₹3.39 in Q1 and ₹3.90 in Q1 FY24 |
| H1 revenue | $118 million, constant currency growth of 23.1% YoY |
| H1 total income | ₹1,038 crores, growth of 24.5% YoY |
| H1 EBITDA margin | 22.7%, in line with full-year guided range of 20% to 22% |
| DSO | 83 days |
| Cash on books | ~₹1,470 crores |
| H1 free cash conversion | ~₹232 crores, approximately 98.4% of EBITDA |
| ROCE | 23.1% |
| ROE | 13.5% |
| Headcount | 6,580 Happiest Minds |
| Trailing 12-month attrition | 14.4%, up from 13.5% in Q1 |
| Utilization | 76.3%, down from 78.2% in Q1; GenAI utilization at 20% to 25% |
| Total customers | 281 |
| Million-dollar customers | 59, up from 58 in Q1 |
| Billion-dollar corporation customers | 82 |
| Average revenue per customer | $842,000 |
| Repeat sales | 95% |
| $3 million to $5 million customers | 6, increased by 4 during the quarter |
| Net Promoter Score | 65 |
| GenAI specialists | 120, supported by 350+ AI specialized workforce, working on 25 projects |
| Interim dividend | ₹2.50 per equity share, record date November 27, 2024; cash outflow ~₹38 crores |
| Full-year revenue growth guidance | 30% to 35% |
| Medium-term EBITDA margin guidance | 20% to 22% |
| Exit run rate | ~$280 million for the fiscal year |